Share on StockTwits
 

Analysts at Leerink Swann lowered their target price on shares of KaloBios Pharmaceuticals (NASDAQ:KBIO) from $15.00 to $7.00 in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports. Leerink Swann’s target price suggests a potential upside of 110.21% from the stock’s previous close.

KaloBios Pharmaceuticals (NASDAQ:KBIO) traded down 28.39% on Thursday, hitting $3.33. The stock had a trading volume of 4,468,707 shares. KaloBios Pharmaceuticals has a one year low of $3.60 and a one year high of $8.25. The stock has a 50-day moving average of $4.48 and a 200-day moving average of $4.8. The company’s market cap is $109.6 million.

KaloBios Pharmaceuticals (NASDAQ:KBIO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter. Analysts expect that KaloBios Pharmaceuticals will post $-1.87 EPS for the current fiscal year.

KaloBios Pharmaceuticals, Inc, is a United States-based company, which develops protein therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.